

## Xembify Connexions™ Copay Program Terms and Conditions

- The Xembify Connexions Copay Program is available to new or existing patients with a valid, on-label prescription for XEMBIFY® (immune globulin subcutaneous human–klhw) 20%
- To be eligible for copay assistance, patients must enroll in the Xembify Connexions support program by fully completing and submitting the required enrollment form
- Copay assistance under the Xembify Connexions Copay Program is for the exclusive benefit of the named patient and is nontransferable to any other person or entity
- Offer is only valid for US citizens or legal residents in the US. Not valid for Puerto Rico or US territories. Residents of certain US states may NOT be eligible to participate in the program (subject to state law)
- Patients may be eligible if they have commercial or private prescription insurance coverage for XEMBIFY
- Eligible patients may pay \$0 copay for XEMBIFY. Benefits may be claimed only for product costs not covered by the patient's commercial or private prescription insurance such as: deductibles, copayments, or coinsurance medication costs for XEMBIFY. Maximum benefit permitted under this program is \$10,000 per calendar year
- This offer cannot be combined with any other coupon, discount, prescription savings card, free trial, or other offer
- Patients must NOT have drug coverage under any federally funded healthcare program including, but not limited to: Medicare, Medicaid, TRICARE®, Department of Defense, Veterans Administration, or any other federal or state-funded healthcare program (collectively, Federal Healthcare Program or "FHCP"). Patients with this type of coverage will be ineligible to participate
- Patients must confirm that they will not submit out-of-pocket costs paid by this program as a claim for payment to any third-party payer, pharmaceutical patient assistance foundation, or account such as a Flexible Spending Account (FSA), a Health Savings Account (HSA), or a Health Reimbursement Account (HRA)
- If their insurance situation changes, it is the patient's responsibility to notify the Xembify Connexions Copay Program at 1-855-636-8715 so that eligibility can be reassessed under the patient's new insurance coverage
- It is important that patients understand that they will be asked to provide personal information that may include their name, address, phone number, email address, and other information related to their insurance and treatment. This information is necessary to permit Grifols, the maker of XEMBIFY, and companies that work with Grifols (including affiliates and third-party service providers) to enroll patients in the Xembify Connexions Copay Program. Grifols may also use the provided information to learn more about the people who use XEMBIFY, and to improve the information we provide to people who are being treated with XEMBIFY. Grifols will not share patient's information with anyone else except as required by law
- As a condition of participating in this program, patients must ensure that they comply with any cost-sharing (copayments, coupons, rebates) disclosure requirements of their insurance carrier or third-party payer, including disclosing to their insurer the amount of financial support they receive from this program
- Grifols reserves the right to rescind, revoke, or amend the program at any time without notice

Please see Important Safety Information on the following pages and refer to accompanying full [Prescribing Information for XEMBIFY](#).

### **What is XEMBIFY®?**

XEMBIFY® (immune globulin subcutaneous human–klhw) is a 20% immune globulin used in the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.

### **IMPORTANT SAFETY INFORMATION**

#### **WARNING: THROMBOSIS**

- **Thrombosis (formation of blood clots within blood vessels) may occur with immune globulin products, including XEMBIFY. Before you take XEMBIFY, talk to your doctor if you:**
  - Are older
  - Are sedentary (need to lie down or sit down) for long periods of time
  - Are taking estrogen-containing medicines (birth control pills, hormone replacement therapy)
  - Have a permanent intravenous (IV) catheter
  - Have hyperviscosity of the blood (diseases such as multiple myeloma or other causes of elevated proteins in the blood)
  - Have cardiovascular (heart) problems or previous history of stroke
- **Thrombosis may occur even if you don't have any risk factors**
- **If you are at risk of thrombosis, your doctor may prescribe XEMBIFY at the minimum dose and infusion rate. Make sure you drink plenty of fluid before taking XEMBIFY. Make sure your doctor is checking you regularly for signs and symptoms of thrombosis and is checking your blood viscosity if you are at risk of hyperviscosity**

#### **Who should not use XEMBIFY?**

- XEMBIFY should not be used if you have had a severe allergic reaction to human immune globulin, or if you have been told by a doctor that you are IgA deficient and have developed antibodies to IgA and hypersensitivity after exposure to a previous plasma product

#### **What are possible serious side effects of XEMBIFY?**

- **Hypersensitivity.** Severe allergic reactions may occur with immune globulin products, including XEMBIFY. If you have a severe allergic reaction, stop the infusion immediately and get medical attention. XEMBIFY contains IgA. If you have known antibodies to IgA, you may have a greater risk of developing potentially severe allergic reactions
- **Aseptic meningitis syndrome (AMS).** Aseptic meningitis is a non-infectious inflammation of the membranes that cover the brain. It causes a severe headache syndrome, which may occur with human immune globulin treatment, including XEMBIFY. If you are showing signs and symptoms of AMS, your doctor may conduct a thorough neurological evaluation including spinal tap (sampling fluid which surrounds the spinal cord) to rule out other causes of meningitis. Stopping human immune globulin treatment has resulted in the end of signs and symptoms within several days. Treatment may include analgesics (pain medicines) and/or a special procedure known as a "blood patch" to stop headache
- **Kidney problems or failure.** Kidney problems or failure may occur with use of human immune globulin products, especially those containing sucrose (sugar). XEMBIFY does not contain sucrose. If you have kidney disease or diabetes with kidney involvement, your doctor should perform a blood test to assess your hydration level and kidney function before beginning immune globulin treatment and at appropriate intervals thereafter. If your doctor determines that kidney function is worsening, they may discontinue treatment
- **Hemolysis.** Your doctor should monitor you for symptoms of hemolysis (destruction of red blood cells causing anemia, or low red blood cell count). If your doctor suspects hemolysis, they should perform additional tests to confirm
- **Transfusion-related acute lung injury (TRALI).** TRALI is a rare but serious syndrome characterized by sudden acute respiratory distress following transfusion. If your doctor suspects TRALI, they will monitor you for any other lung issues. TRALI may be managed with oxygen therapy

### **IMPORTANT SAFETY INFORMATION (cont.)**

- **Transmissible infectious agents.** Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases or CJD have been associated with the use of XEMBIFY
- **Interference with lab tests.** Because XEMBIFY contains a variety of antibodies, blood tests to determine antibody levels may be falsely elevated. Be sure to tell your doctor or lab technician that you are using XEMBIFY

### **What are other possible side effects of XEMBIFY?**

- In clinical studies of XEMBIFY, some patients experienced local side effects (at the injection site) including pain, redness, puffiness, bruising, nodules, itching, firmness, scabbing and swelling at the site on the skin where the injection occurred. Some patients experienced non-injection-site side effects including cough and diarrhea
- Use of XEMBIFY may interfere with the immune response to virus vaccines, such as vaccines for measles, mumps, rubella and varicella. Tell your doctor you are taking XEMBIFY before getting vaccinations

**Please see accompanying full [Prescribing Information for XEMBIFY](#).**

**You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.**